This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Life Sciences
Innovation in life sciences demands large investments, so safeguarding your advancements in a highly competitive and evolving landscape is key.
At Sterlington, our experienced attorneys leverage their deep technical industry knowledge and extensive litigation experience to both protect the intellectual property of our life sciences clients, and to defend and enforce their rights.
We represent life sciences companies in IP litigation, patent and regulatory strategy, commercial disputes, and transactions. Our life sciences clients range from start-ups developing cutting-edge technologies to producers of some of the world’s leading medicines.
Our IP trial lawyers have extensive experience representing innovator pharmaceutical companies in patent litigation against generic manufacturers under the Hatch-Waxman Act, as well as advising biologic manufacturers under the Biologics Price Competition and Innovation Act. We also represent our life sciences clients in mergers, acquisitions, joint ventures, licenses, spinouts, financings, and other corporate transactions.
In addition to our deep experience with small-molecule products, pharmaceutical formulations, biologics, medical devices, and diagnostics, we have extensive experience with emerging technologies such as lipid nano-particles, chemically-modified biologics, CRISPR, CAR-T cells, and other novel drug technologies.